Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Chessum NEA"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Liu M; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., Mirza A; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., McAndrew PC; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., Thapaliya A; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., Pierrat OA; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., Stubbs M; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., Hahner T; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., Chessum NEA; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., Innocenti P; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., Caldwell J; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., Cheeseman MD; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., Bellenie BR; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., van Montfort RLM; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K.; Division of Structural Biology, The Institute of Cancer Research, London SM2 5NG, U.K., Newton GK; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., Burke R; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., Collins I; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., Hoelder S; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K.
Publikováno v:
Journal of medicinal chemistry [J Med Chem] 2023 Aug 10; Vol. 66 (15), pp. 10617-10627. Date of Electronic Publication: 2023 Jul 19.
Autor:
Pasqua AE; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Sharp SY; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Chessum NEA; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Hayes A; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Pellegrino L; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Tucker MJ; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Miah A; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Wilding B; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Evans LE; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Rye CS; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Mok NY; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Liu M; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Henley AT; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Gowan S; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., De Billy E; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Te Poele R; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Powers M; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Eccles SA; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Clarke PA; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Raynaud FI; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Workman P; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Jones K; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom., Cheeseman MD; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom.
Publikováno v:
Journal of medicinal chemistry [J Med Chem] 2023 Apr 27; Vol. 66 (8), pp. 5907-5936. Date of Electronic Publication: 2023 Apr 05.
Autor:
Meyers J; Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, United Kingdom., Chessum NEA; Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, United Kingdom., Ali S; Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, United Kingdom., Mok NY; Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, United Kingdom., Wilding B; Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, United Kingdom., Pasqua AE; Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, United Kingdom., Rowlands M; Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, United Kingdom., Tucker MJ; Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, United Kingdom., Evans LE; Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, United Kingdom., Rye CS; Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, United Kingdom., O'Fee L; Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, United Kingdom., Le Bihan YV; Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, United Kingdom., Burke R; Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, United Kingdom., Carter M; Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, United Kingdom., Workman P; Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, United Kingdom., Blagg J; Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, United Kingdom., Brown N; Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, United Kingdom., van Montfort RLM; Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, United Kingdom., Jones K; Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, United Kingdom., Cheeseman MD; Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, United Kingdom.
Publikováno v:
ACS medicinal chemistry letters [ACS Med Chem Lett] 2018 Nov 16; Vol. 9 (12), pp. 1199-1204. Date of Electronic Publication: 2018 Nov 16 (Print Publication: 2018).
Autor:
Fok JHL; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Hedayat S; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Zhang L; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Aronson LI; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Mirabella F; Division of Molecular Pathology, The Institute of Cancer Research, Sutton, London, United Kingdom., Pawlyn C; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Bright MD; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Wardell CP; Division of Molecular Pathology, The Institute of Cancer Research, Sutton, London, United Kingdom.; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas., Keats JJ; Translational Genomics Research Institute (TGen), Phoenix, Arizona., De Billy E; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Rye CS; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Chessum NEA; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Jones K; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Morgan GJ; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas., Eccles SA; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Workman P; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Davies FE; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom. fedavies@uams.edu.; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2018 May 15; Vol. 24 (10), pp. 2395-2407. Date of Electronic Publication: 2018 Feb 01.
Autor:
Chessum NEA; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SW7 3RP, United Kingdom., Sharp SY; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SW7 3RP, United Kingdom., Caldwell JJ; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SW7 3RP, United Kingdom., Pasqua AE; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SW7 3RP, United Kingdom., Wilding B; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SW7 3RP, United Kingdom., Colombano G; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SW7 3RP, United Kingdom., Collins I; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SW7 3RP, United Kingdom., Ozer B; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SW7 3RP, United Kingdom., Richards M; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SW7 3RP, United Kingdom., Rowlands M; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SW7 3RP, United Kingdom., Stubbs M; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SW7 3RP, United Kingdom., Burke R; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SW7 3RP, United Kingdom., McAndrew PC; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SW7 3RP, United Kingdom., Clarke PA; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SW7 3RP, United Kingdom., Workman P; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SW7 3RP, United Kingdom., Cheeseman MD; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SW7 3RP, United Kingdom., Jones K; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SW7 3RP, United Kingdom.
Publikováno v:
Journal of medicinal chemistry [J Med Chem] 2018 Feb 08; Vol. 61 (3), pp. 918-933. Date of Electronic Publication: 2018 Jan 05.